plerixafor has been researched along with incb-018424 in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bouchlaka, MN; Capitini, CM; Cho, MM; Feils, AS; Gavcovich, TB; Hess, NJ; Kabakov, SA; Olson, SL; Quamine, AE; Rinella, SP; Rui, L; Turicek, DP; Walker, KL; Zhu, F | 1 |
1 other study(ies) available for plerixafor and incb-018424
| Article | Year |
|---|---|
CXCR4 allows T cell acute lymphoblastic leukemia to escape from JAK1/2 and BCL2 inhibition through CNS infiltration.
Topics: Benzylamines; Bridged Bicyclo Compounds, Heterocyclic; Central Nervous System; Cyclams; Hematopoietic Stem Cell Mobilization; Humans; Janus Kinase 1; Nitriles; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Proto-Oncogene Proteins c-bcl-2; Pyrazoles; Pyrimidines; Receptors, CXCR4; Sulfonamides | 2021 |